Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL-0719 in Healthy Subjects and Cold Agglutinin Disease
NCT05318534Phase 1Recruiting
- Sponsor
- Gliknik
- Start
- Apr 2022
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in cold agglutinin disease (CAD) comparing GL-0719 with Placebo (2 arms). Primary endpoints: Adverse Events, Laboratory abnormalities and 1 more. Started Apr 2022; status: recruiting.
02
Drugs
GL-0719
03
Conditions
cold agglutinin disease (CAD)
Beyond the preview
Go deeper on NCT05318534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05318534.